- Home
- RVPHW vs VLYPO Comparison
RVPHW vs VLYPO Comparison
Compare RVPHW & VLYPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- VLYPO
- Stock Information
- Founded
- RVPHW 2018
- VLYPO N/A
- Country
- RVPHW United States
- VLYPO United States
- Employees
- RVPHW 14
- VLYPO 3732
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- VLYPO Major Banks
- Sector
- RVPHW Health Care
- VLYPO Finance
- Exchange
- RVPHW Nasdaq
- VLYPO Nasdaq
- Market Cap
- RVPHW N/A
- VLYPO N/A
- IPO Year
- RVPHW N/A
- VLYPO N/A
- Fundamental
- Price
- RVPHW $0.03
- VLYPO $24.68
- Analyst Decision
- RVPHW
- VLYPO
- Analyst Count
- RVPHW 0
- VLYPO 0
- Target Price
- RVPHW N/A
- VLYPO N/A
- AVG Volume (30 Days)
- RVPHW 22.4K
- VLYPO N/A
- Earning Date
- RVPHW 03-14-2025
- VLYPO N/A
- Dividend Yield
- RVPHW N/A
- VLYPO N/A
- EPS Growth
- RVPHW N/A
- VLYPO N/A
- EPS
- RVPHW N/A
- VLYPO N/A
- Revenue
- RVPHW N/A
- VLYPO N/A
- Revenue This Year
- RVPHW N/A
- VLYPO N/A
- Revenue Next Year
- RVPHW N/A
- VLYPO N/A
- P/E Ratio
- RVPHW N/A
- VLYPO N/A
- Revenue Growth
- RVPHW N/A
- VLYPO N/A
- 52 Week Low
- RVPHW $0.13
- VLYPO N/A
- 52 Week High
- RVPHW $0.15
- VLYPO N/A
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- VLYPO 47.29
- Support Level
- RVPHW N/A
- VLYPO $24.69
- Resistance Level
- RVPHW N/A
- VLYPO $24.80
- Average True Range (ATR)
- RVPHW 0.00
- VLYPO 0.22
- MACD
- RVPHW 0.00
- VLYPO -0.03
- Stochastic Oscillator
- RVPHW 0.00
- VLYPO 39.68
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.